Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
AIChE Annual MeetingAIChE Annual Meeting
Not Confirmed
Not Confirmed
02-06 November, 2025
Not Confirmed
Not Confirmed
03-06 November, 2025
Not Confirmed
Not Confirmed
03-05 November, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS






Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
AIChE Annual MeetingAIChE Annual Meeting
Industry Trade Show
Not Confirmed
02-06 November, 2025
Industry Trade Show
Not Confirmed
03-06 November, 2025
Industry Trade Show
Not Confirmed
03-05 November, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/we-re-expanding-our-cdmo-capabilities-to-meet-the-next-wave-of-complex-therapies-starting-with-oncology
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-chemexpress-invest-in-adc-facilities-cohance-to-set-up-oligonucleotide-facility-in-india

19 Sep 2025
// INDPHARMAPOST
https://www.indianpharmapost.com/diagnostic-center/curateq-biologics-completes-phase-3-clinical-study-for-denosumab-biosimilar-17842

27 Aug 2025
// BUSINESS STD
https://www.business-standard.com/industry/news/aurobindo-pharma-subsidiary-uk-approval-breast-cancer-drug-dazublys-125082601330_1.html

30 Jun 2025
// EMA
https://www.ema.europa.eu/en/documents/overview/dazublys-epar-medicine-overview_en.pdf

14 May 2025
// THEHINDU
https://www.thehindu.com/business/aurobindo-pharma-arms-biosimilar-gets-marketing-nod-from-uks-mhra/article69572375.ece

28 Apr 2025
// INDPHARMAPOST
https://www.indianpharmapost.com/drug-approval/curateq-biologics-receives-positive-opinion-for-biosimilar-dazublys-from-ema-17080

09 Apr 2025
// INDPHARMAPOST
https://www.indianpharmapost.com/news/curateq-biologics-completes-phase-1-pharmacokinetics-study-of-biosimilar-denosumab-17000
ABOUT THIS PAGE